Earlier this week, 18 people in North Carolina reported side effects, while 11 people in Colorado reacted to the shot with symptoms ranging from dizziness, nausea and fainting, CBS News reported.

“This is a really potent vaccine, and what we’re seeing is some of that potency relating at a very rare side effect that we just have to be aware of,” said Dr. David Agus, a CBS News medical contributor.

All three major US vaccines produced adverse reactions in more than 60,000 people nationwide. For each manufacturer — Pfizer, Moderna and Johnson & Johnson — just one-tenth of 1% of all people have reported side effects.

Another problem facing Johnson & Johnson is distribution. The company is dramatically scaling back shipments to states by 86% next week.

Meanwhile, Michigan is experiencing dreadful deja vu as some hospital intensive care units near capacity.

“We all know what works and this has to be a team effort. We have to do this together. Lives depend on it,” Michigan Governor Gretchen Whitmer stated.

Whitmer is asking for a two-week pause on indoor dining, in-person learning for high schools and youth sports — a driving factor in new cases among kids.

Pfizer is the first company to seek an expansion of its emergency use authorization to give its vaccine to children as young as 12.

In California, thousands were turned away after being told to show up to one site with extra doses. In New York City, variants comprise nearly 80% of new daily cases, with 45% homegrown. Another 30% are driven by the variant first discovered in the UK, which is believed to be up to 70% more contagious and more lethal.

Agus is warning Americans not to panic.

“The current vaccines that are out there in the public work against all of the variants,” the CBS News medical contributor noted, adding, “Science is overcoming here. And that’s why I think that by June we’re going to overcome this virus in the United States and get to a new normal here.”

Of the four serious cases of clotting and low platelets, three occurred in the US during the rollout of J&J’s vaccine from its Janssen pharmaceuticals unit, the European Medicines Agency (EMA) said on Friday, adding that one person had died and one case was reported in a clinical trial, The Guardian reported.

It was the first news of EMA’s inquiry into the J&J vaccine.

The EMA has already confirmed possible links between AstraZeneca’s coronavirus vaccine and very rare blood clots in the brain and abdomen.

J&J, which is based in the US, added it was aware of the reports of blood clots possibly related to its COVID vaccine and others, and was working with regulators to assess the data and provide relevant information.

“At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine,” the company said in an emailed statement.

The EMA also noted it was not yet clear if there was a link between the two vaccines and the reported conditions, and that its safety committee would decide if regulatory action such as label changes were needed.

Some countries in Europe and Asia have restricted the use of AstraZeneca’s vaccine, Vaxzevria, in younger people after an update by EU and UK regulators this week that found a link between the events and the shot. Regulators have announced the benefits of the vaccine outweigh the risks.

J&J’s single-dose vaccine has been approved for EU use but the rollout has yet to begin. It is mainly being used in the US.

The EMA also stated five cases of capillary leak syndrome in people who received AstraZeneca’s vaccine were reported.

The condition, in which blood leaks from the smallest of vessels into muscles and body cavities, is characterised by swelling and a drop in blood pressure.

The J&J and AstraZeneca shots are two of the four approved COVID vaccinations in Europe.